Anderson-Fabry disease: Long-term echocardiographic follow-up under enzyme replacement therapy

European Journal of Echocardiography

Volumn 9, Issue 6, 2008, Pages 729-735

  Kovacevic Preradovic, T ^a   Zuber, M ^a   Jost, C H Attenhofer ^b   Widmer, U ^c   Seifert, B ^c   Schulthess, G ^c   Fischer, A ^a   Jenni, R ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b KLINIK IM PARK   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Anderson Fabry disease; Cardiac function; Enzyme replacement therapy; Left ventricular hypertrophy; Long term follow up

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; CREATINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HEART MUSCLE FIBROSIS; HEART VENTRICLE SEPTUM; HUMAN; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ALPHA-GALACTOSIDASE; COHORT STUDIES; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; FABRY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 54949143668     PISSN: 15252167     EISSN: 15322114     Source Type: Journal    
DOI: 10.1093/ejechocard/jen129     Document Type: Article

References (33)

1. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.
2. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 2007;93:528-35.
3. Kampmann C, Wiethoff CM, Perrot A, Beck M, Dietz R, Osterziel KJ. The heart in Anderson Fabry disease. Z Kardiol 2002;91:786-95.
4. Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ. Echocardiographic abnormalities and disease severity in Fabry's disease. J Am Coll Cardiol 1986;7:1157-61.
5. Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudová J, Karetová D, Zeman J, Ledvinová J, Poupetová H, Elleder M, Aschermann M. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000;139:1101-8.
6. Pastores GM, Thadhani R. Advances in the management of Anderson-Fabry disease: enzyme replacement therapy. Expert Opin Biol Ther 2002;2:325-33.
7. Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9.
8. Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004;34:838-44.
9. Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis 2003;26:617-27.
10. Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, Baehner F, Kim K, Bajbouj M, Schwarting A, Gal A, Beck M. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004;65:299-307.
11. Oh JK, Appleton CP, Hatle LK, Nishimura RA, Seward JB, Tajik AJ. The noninvasive assessment of left ventricular diastolic function with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 1997;10:246-70.
12. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8.
13. Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987;59:956-60.
14. Jenni R, Vieli A, Hess O, Anliker M, Krayenbuehl HP. Estimation of left ventricular volume from apical orthogonal 2-D echocardiograms. Eur Heart J 1981;2:217-25.
15. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
16. Beer M, Weidemann F, Breunig F, Knoll A, Koeppe S, Machann W, Hahn D, Wanner C, Strotmann J, Sandstede J. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 2006;97:1515-8.
17. Pieroni M, Chimenti C, De Cobelli F, Morgante E, Del Maschio A, Gaudio C, Russo MA, Frustaci A. Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll Cardiol 2006;47:1663-71.
18. Khouri SJ, Maly GT, Suh DD, Walsh TE. A practical approach to the echocardiographic evaluation of diastolic function. J Am Soc Echocardiogr 2004;17:290-7.
19. Lidove O, Joly D, Barbey F, Bekri S, Alexandra JF, Peigne V, Jaussaud R, Papo T. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract 2007;61:293- 302.
20. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003;108:1299-301.
21. Spinelli L, Pisani A, Sabbatini M, Petretta M, Andreucci MV, Procaccini D, Lo Surdo N, Federico S, Cianciaruso B. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet 2004;66:158-65.
22. Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, Elliott PM; European FOS Investigators. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007;28:1228-35.
23. Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, Thaman R, Tome MT, McKenna WJ, Lee P, Camici PG. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 2006;92:357-60.
24. Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfa. Heart 2008;94:153-8.
25. Shah JS, Lee P, Hughes D et al. The natural history of left ventricular systolic function in Anderson-Fabry disease. Heart 2005;91:533-4.
26. Pieroni M, Chimenti C, Russo A, Russo MA, Maseri A, Frustaci A. Tissue Doppler imaging in Fabry disease. Curr Opin Cardiol 2004;19:452-7.
27. Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003;107:1978-84.
28. Sengupta PP, Krishnamoorthy VK, Korinek J, Narula J, Vannan MA, Lester SJ, Tajik JA, Seward JB, Khandheria BK, Belohlavek M. Left ventricular form and function revisited: applied translational science to cardiovascular ultrasound imaging. J Am Soc Echocardiogr 2007;20:539-51.
29. Flachskampf FA, Voigt JU. The interventricular septum is functionally bilayered: a fresh look at a well known structure. Heart 2005;91:1260-1.
30. Wickline SA, Verdonk ED, Miller JG. Three-dimensional characterization of human ventricular myofiber architecture by ultrasonic backscatter. J Clin Invest 1991;88:438-46.
31. Recchia D, Miller JG, Wickline SA. Quantification of ultrasonic anisotropy in normal myocardium with lateral gain compensation of two-dimensional integrated backscatter images. Ultrasound Med Biol 1993;19:497-505.
32. Sosnovik DE, Baldwin SL, Lewis SH, Holland MR, Miller JG. Transmural variation of myocardial attenuation measured with a clinical imager. Ultrasound Med Biol 2001;27:1643-50.
33. Weidemann F, Niemann M, Herrmann S, Kung M, Störk S, Waller C, Beer M, Breunig F, Wanner C, Voelker W, Ertl G, Bijnens B, Strotmann JM. A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium. Eur Heart J 2007;28:3020-6.